Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding (NCT05060731) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding
Hungary570 participantsStarted 2025-09-01
Plain-language summary
Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation. However, the dose and route of the administration are still a question. The FIERCE clinical trial aims to compare the effect of intravenous iron supplementation and oral iron replacement on mortality, unplanned emergency visits, and hospital readmissions in multimorbid patients with acute nonvariceal gastrointestinal bleeding.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
β. 48 hours after the endoscopic diagnosis and/or treatment;
β. hemodynamically stable;
β. the discharge of the patient is planned;
β. hemoglobin level \<10 g/dl on the day of randomisation;
β. 24 hours after the last transfusion and no need for further transfusion;
β. signed informed consent.
Exclusion criteria
β. known hypersensitivity to iron products (mild side effects excluded);
β. previous diagnosis of iron overload \[e.g., transferrin receptor saturation (TSAT) \>50%, ferritin\> 160 for women ng/ml, ferritin \>270 ng/ml for men) or disorders of iron utilisation;
β. pregnancy or breast feeding;
β. diagnosis of iron malabsorption (at discretion of the attending clinician; e.g., severe inflammatory bowel disease, active celiac disease);
β. chronic end stage diseases (chronic heart failure-New York Heart Association Classification class 4, chronic kidney disease (eGFR \<30 mL/min/1.73 m2) with or without dialysis, liver cirrhosis with Child Pugh C score, chronic kidney disease with dialysis, chronic obstructive pulmonary disease stage 4, chronic inflammatory disease, malignancies, AIDS);
β. liver cirrhosis with known varices at high risk of bleeding - endoscopic features of high risk of variceal bleeding or liver stiffness measured by transient elastography \>20 kiloPascal and platelet count \<150 Γ 10\^9 cells/L;
β. gastrointestinal tract malignancies with high risk of gastrointestinal bleeding;